Clinical-stage immuno-oncology company Agenus builds on Genedata’s E2E biopharma discovery system to streamline cancer immunotherapy R&D
Clinical-stage immuno-oncology company Agenus builds on Genedata’s E2E biopharma discovery system to streamline cancer immunotherapy R&D
Basel, Switzerland – December 3, 2019 – Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Agenus, a clinical-stage immuno-oncology company developing therapies to fight cancer, has chosen Genedata Biologics® as a part of their antibody R&D workflow platform. Agenus will use the platform to support immunotherapy and vaccine pipeline programs across their global organization.
“Genedata Biologics was the clear choice as a backbone system to support the full diversity of our complex and rapidly evolving antibody discovery processes in the US and the UK,” said Dennis Underwood, Ph.D., VP Molecular and Information Systems at Agenus. The platform helps streamline Agenus’s growing pipeline of checkpoint-inhibitor candidates and simultaneously supports screening, engineering, expression, purification, and analytics processes for proteins and antibodies, including bispecifics and other innovative next-generation molecules.
Agenus scientists have set path-breaking records delivering new discoveries to the clinic in the past three years. The Genedata Biologics technology, in conjunction with Agenus’s Intelligent (Re)search (AIR) platform, will further augment Agenus scientists’ ability to capture, process, and interpret all large-molecule R&D data and is an important component of the Agenus collaborative data and information platform. Molecule, sample, assay and analytics data, including developability and manufacturability data, are shared between different project teams and sites. This enables systematic and transparent decision-making when selecting therapeutic candidates to be progressed through the clinical development pipeline.
“We are excited that Agenus, a leading company developing unique immune therapies for patients with cancer, has chosen Genedata Biologics as core infrastructure to support their biotherapeutics discovery processes,” said Othmar Pfannes, Ph.D., CEO of Genedata. “This collaboration also demonstrates that innovative, fast-paced biopharma companies can benefit from an integrated data capture and workflow management system. We look forward to a long and productive partnership helping Agenus increase the efficiency of their biologics discovery and development processes.”
About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
www.genedata.com
LinkedIn | Twitter | YouTube
Contact
Miles Fisher-Pollard
Genedata
Public Relations
Phone: +41 61 511 85 61
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
